Massimo Barberi
The agreement covers the development and future commercialization in Europe of VOWST®, the first oral LBP approved in the United States to prevent recurrent Clostridioides difficile infection.
The IPA Europe initiative is designed to bring the scientific, health and socio-economic value of probiotics into a broader public and policy conversation.
CHMP has announced the development of a dedicated reflection paper on the non-clinical development and evaluation of microbiome-based medicinal products (MMPs).
New IPA Europe analysis puts hard numbers on how evidence-based probiotic use could cut healthcare costs and boost productivity across the EU.
